Principal Investigator/Program Director (Last, First, Middle): Chaiken, IfWJn M DESCRIPTION: The main objective of Core B is to provide protein technology services, including protein reagents, ligand binding analyses and methods development, to support investigation of structure-based antagonism of human immunodeficiency virus -1 (HIV-1) entry. HIV-1 infection is initiated by entry of the virus into host cells. Interaction of HIV-1 gp120 envelope protein with host cell receptor, CD4, followed by binding to a co-receptor, most commonly the chemokine receptors CCR5 or CXCR4, are crucial steps in the process of viral entry. The overall goal of this Program Project is to identify agents that will antagonize these protein-binding events. Candidate inhibitors of gp120 interactions will be generated by various members of the Program Project team, in particular, Project 1, Structure analysis of HIV-1 entry inhibition, Project 2, Peptide-inspired competitive and allosteric inhibitors of HIV-1 entry and Project 3, Discovery and synthesis of small-molecule CD4-gp120 antagonists. In order to analyze the efficacy and mechanisms of action of these candidate inhibitors, protein reagents will be required by the above projects, in coordination with Project 4, Assembly and inhibition thermodynamics, and Project 5, Structure-based antagonism of HIV-1 envelope function in cell entry. Furthermore, SPR-based screening of these inhibitor candidates with gp120s from multiple subtypes, both in direct binding and functional assays, will help prioritize thermodynamic investigations, while also aiding the molecular interpretation of biological assays. The data generated through the screening assays also will help test the hypotheses of inhibitor interaction mechanisms developed in Core A, Computational modeling.
The specific aims of Core B are to: (1) Produce, purify and validate protein reagents required by Program Project members, including envelope monomers and trimers from diverse clades of HIV-1, soluble constructs of HIV-1 receptors and antibodies for both purification and characterization studies. (2) Screen kinetic interaction properties of gp120 antagonist candidates for direct interaction and effector activity profiles, which will contribute information that will be invaluable in the compound prioritization process. (3) Develop, validate and implement new technologies for recombinant protein expression, purification and binding assays to serve evolving needs of the Program Project. Transfer new technologies to P01 projects to further enable mechanistic and antagonist design investigations. Overall, this Core will provide Project Team members with a central resource that will both produce and supply high quality protein reagents, in addition to screening candidate antiviral molecules and developing novel assay systems for the investigation of these compounds. The work of Core B will adapt its activities in these areas to the evolving needs of the Projects in order to support investigations of HIV-1 entry antagonism and structure- based antagonist design.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM056550-13
Application #
7667729
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
13
Fiscal Year
2008
Total Cost
$195,137
Indirect Cost
Name
Drexel University
Department
Type
DUNS #
002604817
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Castillo-Menendez, Luis R; Witt, Kristen; Espy, Nicole et al. (2018) Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers. J Virol 92:
Rashad, Adel A; Song, Li-Rui; Holmes, Andrew P et al. (2018) Bifunctional Chimera That Coordinately Targets Human Immunodeficiency Virus 1 Envelope gp120 and the Host-Cell CCR5 Coreceptor at the Virus-Cell Interface. J Med Chem 61:5020-5033
Moraca, Francesca; Rinaldo, David; Smith 3rd, Amos B et al. (2018) Specific Noncovalent Interactions Determine Optimal Structure of a Buried Ligand Moiety: QM/MM and Pure QM Modeling of Complexes of the Small-Molecule CD4 Mimetics and HIV-1 gp120. ChemMedChem 13:627-633
Castillo-Menendez, Luis R; Nguyen, Hanh T; Sodroski, Joseph (2018) Conformational Differences Between Functional Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Trimers and Stabilized Soluble Trimers. J Virol :
Madani, Navid; Princiotto, Amy M; Mach, Linh et al. (2018) A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nat Commun 9:2363
Kisalu, Neville K; Idris, Azza H; Weidle, Connor et al. (2018) A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med 24:408-416
Parajuli, Bibek; Acharya, Kriti; Bach, Harry C et al. (2018) Restricted HIV-1 Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus. Biochem J 475:931-957
Ma, Xiaochu; Lu, Maolin; Gorman, Jason et al. (2018) HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations. Elife 7:
Madani, Navid; Princiotto, Amy M; Zhao, Connie et al. (2017) Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds. J Virol 91:
Prévost, Jérémie; Zoubchenok, Daria; Richard, Jonathan et al. (2017) Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. J Virol 91:

Showing the most recent 10 out of 146 publications